AMRUTANJAN
Amrutanjan Health Care Reports Strong FY26 Performance
Amrutanjan Health Care Limited showcases robust FY26 performance with double-digit growth in key segments.
Amrutanjan Health Care Limited (AMRUTANJAN) has reported a strong performance for the fiscal year ending March 31, 2026. The company witnessed double-digit growth in its key segments, particularly in Pain Management and Women’s Hygiene.
Segment Performance
The Pain Management segment, which includes brands like Amrutanjan and Maha Strong, saw significant growth. Specifically, Back Pain Roll On (BPRO) and Maha Strong contributed to the overall growth with respective increases of 22% and 12%.
New Launches
AMRUTANJAN has also expanded its product portfolio with new launches in personal care, including Women’s Razors, Men’s Razors, Antiseptic Plaster, Ortho Pain Oil, and Nasal Spray. These new additions have been well-received by both retailers and consumers.
Strategic Initiatives
The company continues to focus on strategic initiatives such as increasing market penetration, expanding distribution networks, and enhancing rural market coverage through its Rural Van initiative. These efforts have resulted in positive momentum across key sales metrics.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Amrutanjan Health Care Limited
Amrutanjan Health Care Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Amrutanjan falls 13.5% over three months and has not found a floor yet. Revenue contracts at 3.7% CAGR. That signals structural headwinds, not a short-term blip. The stock gains 2.8% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 3.7% CAGR and the PEG stands at 99.00. The growth does not match the price the market asks. Furthermore, flat price action adds no technical catalyst. A lower price or faster revenue growth would improve the odds. Check Fundamentals of Amrutanjan Health Care Limited.
AMRUTANJAN
Amrutanjan Health Care Limited Q1 FY27: Revenue Up 9.48%, Women’s Hygiene Double Digit Growth
Amrutanjan Health Care Limited reports Q1 FY27 results with a 9.48% revenue increase, driven by double-digit growth in Women’s Hygiene.
Amrutanjan Health Care Limited (NSE: AMRUTANJAN) announced its Q1 FY27 results, showing a robust 9.48% revenue increase. The company’s performance was driven by double-digit growth in the Women’s Hygiene segment.
Business Update
The Women’s Hygiene segment, under the Comfy brand, witnessed a 27.09% growth in net sales. This growth was fueled by the Comfy XL variant and the value pack, which saw increases of 43% and 24% respectively.
Segment Performance
The Pain Management category, contributing to 65% of the company’s revenue, experienced a decline in volume growth due to retailer demand erosion post-GST implementation. However, the Personal Care portfolio, including the Comfy Close and Clean women’s razor and Amrutanjan Smoothe Men’s razor, generated ₹3 crore in revenue this quarter.
Financials
The company’s net sales for Q1 FY27 stood at ₹102.97 crore, up from ₹94.05 crore in the same period last year. Profit before exceptional items and tax was ₹6.07 crore, compared to ₹11.29 crore in Q1 FY26. The profit after tax for the quarter was ₹4.37 crore.
Despite the overall slowdown in the Pain Management category, Amrutanjan Health Care Limited remains optimistic about its strategic initiatives and new product launches, which have shown good acceptance among retailers and consumers.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Amrutanjan Health Care Limited
Amrutanjan Health Care Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Amrutanjan falls 14.9% over three months and has not found a floor yet. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The PEG of 1.83 limits the upside. The stock does not come cheap. Sellers drive 1.7x the volume of buyers. Furthermore, they controlled 17 of recent sessions versus 13 for buyers — a clear distribution signal. Revenue grows at 9.9% CAGR — a respectable pace. However, the stock drops 14.9% in three months without an obvious fundamental trigger. Sector-wide pressure or a valuation re-rating can persist for longer than expected. Therefore, there is no rush to step in. Check Fundamentals of Amrutanjan Health Care Limited.
-
PINELABS3 days agoPine Labs Limited (pinelabs) Collaborates with Google Cloud to Advance Agentic Commerce in India
-
Consumer Cyclical3 days agoThomas Cook (india) Limited Expands Retail Presence in Karnataka
-
BALRAMCHIN3 days agoBalrampur Chini Mills Limited (balramchin) Wins ₹75 Crore Bioe3 Grant
-
Consumer Cyclical3 days agoCrompton Greaves Consumer Electricals Limited Introduces Galaxy Festive Lights Range to Brighten Homes This Festive Season
-
Basic Materials2 days agoBharat Coking Coal Limited (bharatcoal) Signs Mou to Boost Domestic Coking Coal Production
-
Consumer Cyclical3 days agoFsn E-commerce Ventures Limited (nykaa) Partners with L’oréal’s BOLD to Back Indian Beauty Startups
-
Consumer Cyclical3 days agoRbz Jewellers Limited (rbzjewel) Expands Retail Footprint with 10,000 Sq. Ft. Flagship Store in Surat
-
AUBANK3 days agoAu Small Finance Bank Limited Unveils Sustainable Business Model at CIO Roundtable